ESOP22 Jun 2026, 07:00 pm
Nephrocare Health Services Approves ESOP 2026 Scheme
AI Summary
Nephrocare Health Services Ltd announced the approval of the NephroPlus Employee Stock Option Scheme 2026 (ESOP 2026) during its Board meeting on June 22, 2026. The scheme, recommended by the Nomination and Remuneration Committee, is in compliance with SEBI regulations and the Companies Act, 2013. It allows for the grant of up to 20,06,814 stock options, convertible into equity shares, representing approximately 2% of the company's paid-up capital. Additionally, the board approved providing collateral support of up to INR 70 Crore for its Saudi Arabian subsidiary's credit facilities, superseding a previous approval.
Key Highlights
- Board approved NephroPlus Employee Stock Option Scheme 2026.
- Scheme allows grant of up to 20,06,814 stock options.
- Options represent approx. 2% of paid-up equity share capital.
- Approved collateral support of up to INR 70 Crore for subsidiary.
- Scheme requires shareholder and regulatory approvals.
Price Impact
More from NEPHROPLUS